Sequella starts new drug trials - Baltimore Business Journal:

http://www.turismagency.com/content/view/80/794/
After finding that its tuberculosiz drug was safe in a single dose twoyears ago, the Rockville biotech has now begun dosing the firstt of three groups of volunteers in a first-phasew trial to test the drug’s safety when taken on a dail y basis. The drug, which has earned fast-trac k and orphan drug status from the Food and Drug is aimed atfighting drug-sensitivde and drug-resistant strains of The at the is conducting the stud through a contract with Dynport Vaccine Co. LLC. The trialo will take place at the Quintilesa Transnational Phase 1 facility inOverland Kan., the same location as the first trials in 2007.
In Sequella is in its final stages of testing a skin patcbh todiagnose tuberculosis, a product it hopesa to start selling to developing countries by early next year, and recentl y received more than $2.3 millionb in NIH grants to develop two more TB still in preclinical stages.